Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult men and women~* Age 18-49 years~* Who reside geographically close to one of the four study sites in Michigan~Exclusion Criteria:~* Persons with any of the health conditions for which the inactivated vaccine is recommended~* Persons for whom either vaccine is contraindicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- TIV (Type: ACTIVE_COMPARATOR): the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
- LAIV (Type: ACTIVE_COMPARATOR): live-attenuated influenza vaccine Flumist, manufactured by MedImmune
- Placebo (Type: PLACEBO_COMPARATOR): Physiologic saline administered as a nasal spray or intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).